Human B7-1 (CD80) Protein (C-His-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P-) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of Human B7-1 protein exceeds 90%.
Cat #
Size
Price
Quantity
816603
25 ug
$245
816604
100 ug
$595
Product Details
Application
ELISA, BLI
Format
Liquid, Biotinylated
Expression Host
CHO
Target Name
CD80, B7-1, B7, BB1
Species
Human
Sources
Recombinant Human B7-1 (CD80) (Val35-Asn242) with C-terminus His-Avi-tag is expressed in CHO cell. This protein was site-specifically labeled with Biotin by BirA ligase.
accession number
Q68D85
Molecular Weight
The protein has a predicted molecular weight of 27.5 kDa. Under DTT-reducing conditions, it migrates at approximately 45 kDa on SDS-PAGE.
Affinity Tag
C-His-Avi
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
B7-1, also known as CD80, is a cell surface glycoprotein in the immunoglobulin superfamily, expressed on activated B cells, macrophages, and dendritic cells. It interacts with the costimulatory receptors CD28 and CTLA-4 on T cells, playing a pivotal role in regulating T cell activation, tolerance, cytokine production, and the generation of cytotoxic T lymphocytes. Through its interactions with CD28 and CTLA-4, CD80 is involved in both enhancing and inhibiting immune responses, thereby maintaining immune balance. This B7/CD28/CTLA-4 pathway is crucial for controlling immune function and is considered a promising target for therapeutic interventions in autoimmune diseases and cancer.
Human B7-1 (CD80) Protein (C-His-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P-) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of Human B7-1 protein exceeds 90%.
